Jordan Kadish

News
ASTX727, Gilteritinib and Venetoclax Yielded High Remission Rates in Patients With R/R FLT3­ Mutated AML Unfit for Chemotherapy
02/10/2023
A phase 1/2 study found that the combination of ASTX727, gilteritinib, and venetoclax yielded high remission rates for patients with R/R FLT3-mutated AML or who are unable to receive chemotherapy.
A phase 1/2 study found that the combination of ASTX727, gilteritinib, and venetoclax yielded high remission rates for patients with R/R FLT3-mutated AML or who are unable to receive chemotherapy.
A phase 1/2 study found that the...
02/10/2023
Oncology
News
Ciltacabtagene Autoleucel CAR−T-Cell Therapy for Patients With Multiple Myeloma
03/09/2023
Ciltacabtagene autoleucel CAR-T-cell therapy produced favorable results among patients with relapsed/refractory multiple myeloma previously exposed to noncellular anti-BCMA therapies.
Ciltacabtagene autoleucel CAR-T-cell therapy produced favorable results among patients with relapsed/refractory multiple myeloma previously exposed to noncellular anti-BCMA therapies.
Ciltacabtagene autoleucel...
03/09/2023
Oncology
News
Atezolizumab Plus R-CHOP Therapy Among Patients With Previously Untreated DLBCL
07/25/2023
Atezolizumab plus R-CHOP demonstrated durable clinical efficacy among patients with previously untreated DLBCL, however the benefit compared with a regimen of R-CHOP alone is likely to be insignificant, according to a phase 1b/2 trial.
Atezolizumab plus R-CHOP demonstrated durable clinical efficacy among patients with previously untreated DLBCL, however the benefit compared with a regimen of R-CHOP alone is likely to be insignificant, according to a phase 1b/2 trial.
Atezolizumab plus R-CHOP...
07/25/2023
Oncology
News
FDA Approves Momelotinib for Patients With Intermediate or High-Risk Myelofibrosis, Including Primary or Secondary MF, With Anemia
09/26/2023
On September 15, 2023, the FDA granted approval for momelotinib for the treatment of intermediate or high-risk myelofibrosis, including primary and secondary myelofibrosis, for patients with anemia.
On September 15, 2023, the FDA granted approval for momelotinib for the treatment of intermediate or high-risk myelofibrosis, including primary and secondary myelofibrosis, for patients with anemia.
On September 15, 2023, the FDA...
09/26/2023
Oncology
News
Brentuximab Vedotin-AVD Yields Encouraging Efficacy and Tolerable Safety Among Patients With Classical Hodgkin Lymphoma and HIV
11/10/2023
Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (AVD) yielded encouraging response rates and tolerable safety among patients with classical Hodgkin lymphoma and HIV.
Brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (AVD) yielded encouraging response rates and tolerable safety among patients with classical Hodgkin lymphoma and HIV.
Brentuximab vedotin with...
11/10/2023
Oncology
News
Haploidentical Donors as an Option for Patients With Myelodysplastic Syndrome
04/06/2023
According to findings of a retrospective multicenter study, haploidentical donors may be a comparable option to HLA-matched unrelated donors for high-risk myelodysplastic syndrome, but have a higher incidence of acute GVHD.
According to findings of a retrospective multicenter study, haploidentical donors may be a comparable option to HLA-matched unrelated donors for high-risk myelodysplastic syndrome, but have a higher incidence of acute GVHD.
According to findings of a...
04/06/2023
Oncology
News
Ibrutinib Demonstrated Efficacy Among Patients With Heavily Pretreated R/R MCL
05/01/2023
Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.
Findings from a multicenter real-world retrospective analysis indicate that BTK inhibitor ibrutinib demonstrated good efficacy among patients with heavily pretreated R/R mantle cell lymphoma.
Findings from a multicenter...
05/01/2023
Oncology
News
R-CHOP Plus R-BAC Shows Potential as Induction Therapy for Transplant-Eligible Patients With MCL
09/06/2023
The combination of R-CHOP and R-BAC demonstrated efficacy as a potential induction therapy option for transplant-eligible patients with mantle cell lymphoma, according to a retrospective analysis.
The combination of R-CHOP and R-BAC demonstrated efficacy as a potential induction therapy option for transplant-eligible patients with mantle cell lymphoma, according to a retrospective analysis.
The combination of R-CHOP and...
09/06/2023
Oncology
News
BTK Inhibitor Acalabrutinib Plus STAT3 Inhibitor Danvatirsen for R/R DLBCL
11/15/2023
BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen therapy yielded safe and tolerable outcomes among patients with R/R DLBCL, but demonstrated limited efficacy outcomes, according to a phase 1 study.
BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen therapy yielded safe and tolerable outcomes among patients with R/R DLBCL, but demonstrated limited efficacy outcomes, according to a phase 1 study.
BTK inhibitor acalabrutinib plus...
11/15/2023
Oncology
News
Mosunetuzumab Yields Clinically Beneficial Outcomes for Patients With Follicular Lymphoma Treated With 3 or More Lines of Therapy
01/19/2024
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that mosunetuzumab monotherapy demonstrated clinically beneficial outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic therapy.
Real-world data indicated that...
01/19/2024
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use